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Dear Editor,  
Interferons (IFNs) are a group of secreted autocrine and paracrine proteins released by host 
cells that impart resistance against viral infections. IFNs that are produced by virus-infected 
cells help other cells in the proximity to heighten their anti-viral defences. Based on their affin-
ity to bind with various receptors, IFNs are classified into three classes, namely, Type I, Type 
II, and Type III IFNs (Borden et al., 2007). These unique signaling proteins facilitate the tran-
scription of more than 300 IFN-inducible genes, which are also referred to as IFN-stimulated 
genes (ISGs), that actively participate in the process of viral protein synthesis inhibition (Hsu 
et al., 2015). 
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Chronic obstructive pulmonary disease (COPD) is the third leading cause of death world-
wide. In a given population aged more than 45 years, COPD affects at least 10 % of them, 
whereas, it affects more than 50 %, among chronic smokers (Chellappan et al., 2020, Mehta et 
al., 2020). Chronic airway inflammation in COPD is mediated by pro-inflammatory cytokines 
which include several IFNs (Chin et al., 2020). Furthermore, the expression levels of interferon 
stimulated genes – myxovirus resistance gene A (ISG MxA), 2'-5'-oligoadenylate synthase 1, 
and viperin genes are reduced in severe COPD patients.  
Influenza A virus (IAV) infected human primary airway epithelial cells (hPECs) isolated 
from active smokers have shown impaired antiviral responses compared to hPECs isolated from 
non-smokers. IAV triggers the release of an array of IFNs, primarily, IFN-λ 1, IFN-λ 2/3 and 
IFN-β, which in turn stimulate a robust antiviral response in hPECs from non-smokers. In con-
trast, hPECs from smokers showed inhibition of IFN-λ1, IFN-λ 2/3 and IFN-β mRNA responses 
by 96 %, 95 % and 85 %, respectively (Wu et al., 2016). Moreover, there is a downregulation 
of IFN-β signaling in the cell-free sputum supernatant of smokers, when compared to people 
who have never smoked.  
Cigarette smoke extract (CSE) may activate serine phosphorylation driven ubiquitination 
and degradation of the IFN alpha/beta receptor 1 subunit of the Type I IFN receptor. This may 
lead to reduced IFN signaling cascade and a corresponding amount of suppression in the re-
sistance against viral infections (HuangFu et al., 2008). Therefore, COPD patients are likely to 
experience acute infectious exacerbations leading to an increased risk of mortality/morbidity, 
as well as, reduced quality of life and poor prognosis. Moreover, immunolabeling scores of 
IFN-β and its main transcription factor (IRF-7) were reduced up to 65 % and 74 % respectively, 
in epithelial tissues and alveolar macrophages in COPD patients, when compared with non-
COPD patients (Garcia-Valero et al., 2019).  
The use of experimental approaches involving in vitro cell culture systems or in vivo animal 
models have revealed key mechanistic insights, which support the fact that, cigarette smoke 
dampens Type I IFN responses followed by an exaggerated inflammatory response to viral 
infections. An in vivo investigation that employed the elastase-induced experimental emphy-
sema mouse model with C57BL/6J and BALB/cJ mouse strains has reported that, the BALB/cJ 
mice had high levels of interleukin (IL)-17A mRNA and a number of classically (M1) and 
alternatively (M2) activated macrophage genes, whereas, C57BL/6J mice showed high levels 
of IFN-γ. This study demonstrated that mice with different genetic backgrounds show con-
trasting susceptibility to the progression of emphysema, which is a common feature in COPD 
(Limjunyawong et al., 2015). 
Increased airway inflammation was observed in mice exposed to cigarette smoke followed 
by chronic infection with non-typeable Haemophilus influenzae (NTHi) virus compared to air-
exposed controls. NTHi-specific T cells from cigarette smoke-exposed mice generated lower 
levels of IFN-γ and IL-4 (Lugade et al., 2014). IFN-γ may modulate macrophages to increase 
the response to toll-like receptor (TLR) ligands, such as LPS. IFN-γ increases the expression 
levels of TLR2 and TLR4. It further activates the Janus Kinase (JAK)/Signal Transducer and 
Activator of Transcription (STAT) signaling pathway in alveolar macrophage. IFN-γ mediated 
cytokine-expression and STAT1 activation were resistant to corticosteroids (dexamethasone) 
while, JAK/STAT1 inhibition repressed the effect of IFN-γ. Therefore, targeting IFN-γ signal-
ing by JAK inhibitors could be a promising novel therapeutic approach against COPD. 
In an ex vivo study conducted with bronchoalveolar lavage (BAL) cells (95 % were macro-
phages) collected from 7 COPD patients and 10 healthy control subjects, the cells infected with 
live rhinovirus resulted in a 50 % impairment in IFN-α and IFN-λ release from the COPD group 
compared to control. Similarly, the level of IFN-β stimulated by rhinovirus was remarkably 
higher in the healthy control subjects compared with the COPD group. The low levels of IFNs 
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in COPD were correlated with impairment in the induction of the ISG CXCL10 (Mallia et al., 
2011).  
Another study that employed primary bronchial epithelial cells isolated from COPD and 
healthy volunteers, who were infected with Rhinovirus-1B, showed that the cells from COPD 
patients had a higher expression of interleukin (IL)-6, IFNs-β and λ1 when compared to the 
cells from healthy subjects. The pre-treatment of IFN-β/λ1 to cells from COPD patients did not 
change IFN-β expression but resulted in increased levels of IFN-λ1 leading to suppression of 
viral replication. However, this did not raise pro-inflammatory cytokines (Baines et al., 2013). 
Moreover, in vitro experiments conducted in both human alveolar basal epithelial adenocarci-
noma cell line (A549) and primary bronchial epithelial cells showed that, IFN-β exerts not only 
a robust, but also a prolonged protective effect against Rhinovirus infection. The viral RNA 
was found to be reduced in both cell lines after 18 hours of exposure with IFN-β followed by 
infection with rhinovirus for the next 72 hours (Gaajeetaan et al., 2013).  
Similarly, in a lung organ culture model, CSE exposure led to inhibition of IFN-inducible 
protein-10, and mRNA expression. Similarly, there was a reduction of IFN-β mRNA by CSE. 
This suppression was due to oxidative inhibition of viral-mediated induction of the pattern 
recognition receptor RIG-I (Wu et al., 2011). Stimulation of the RIG-I/mitochondrial antiviral 
signaling protein pathway by intracellular delivery of polyinosinic: polycytidylic acid (with 
liposomes or via nucleofection) upregulated IFN-β, mainly through the TLR3/TRIF pathway 
in primary airway epithelial cells with low co-stimulation of IL-8. This study highlights the 
feasibility of augmenting the production of IFN-β by airway epithelial cells without excessive 
co-stimulation of IL-8 (Dauletbaev et al., 2015).   
A collective and comprehensive understanding of the role of IFNs in the pathogenesis of 
COPD may provide us with a promising platform to understand the in-depth disease mechanism 
and would provide a logical understanding to investigate potential therapeutic alternatives. 
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